BioRem Statistics
Total Valuation
BioRem has a market cap or net worth of 23.55 million. The enterprise value is 22.36 million.
| Market Cap | 23.55M |
| Enterprise Value | 22.36M |
Important Dates
The next estimated earnings date is Friday, May 23, 2025.
| Earnings Date | May 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 15.70M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.59% |
| Shares Change (QoQ) | -16.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 15.39M |
Valuation Ratios
The trailing PE ratio is 11.13.
| PE Ratio | 11.13 |
| Forward PE | n/a |
| PS Ratio | 0.91 |
| PB Ratio | 3.19 |
| P/TBV Ratio | 3.19 |
| P/FCF Ratio | 10.23 |
| P/OCF Ratio | 9.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.43, with an EV/FCF ratio of 9.71.
| EV / Earnings | 10.57 |
| EV / Sales | 0.84 |
| EV / EBITDA | 6.43 |
| EV / EBIT | 7.13 |
| EV / FCF | 9.71 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.63 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | 1.07 |
| Interest Coverage | 22.56 |
Financial Efficiency
Return on equity (ROE) is 35.10% and return on invested capital (ROIC) is 21.89%.
| Return on Equity (ROE) | 35.10% |
| Return on Assets (ROA) | 10.44% |
| Return on Invested Capital (ROIC) | 21.89% |
| Return on Capital Employed (ROCE) | 32.57% |
| Revenue Per Employee | 764,892 |
| Profits Per Employee | 62,218 |
| Employee Count | 34 |
| Asset Turnover | 1.42 |
| Inventory Turnover | 14.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.86% in the last 52 weeks. The beta is 0.77, so BioRem's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | +3.86% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 1.81 |
| Relative Strength Index (RSI) | 53.56 |
| Average Volume (20 Days) | 2,823 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioRem had revenue of 26.01 million and earned 2.12 million in profits. Earnings per share was 0.11.
| Revenue | 26.01M |
| Gross Profit | 6.99M |
| Operating Income | 3.05M |
| Pretax Income | 2.88M |
| Net Income | 2.12M |
| EBITDA | 3.25M |
| EBIT | 3.05M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
The company has 3.62 million in cash and 2.47 million in debt, giving a net cash position of 1.15 million.
| Cash & Cash Equivalents | 3.62M |
| Total Debt | 2.47M |
| Net Cash | 1.15M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 7.38M |
| Book Value Per Share | 0.47 |
| Working Capital | 6.61M |
Cash Flow
In the last 12 months, operating cash flow was 2.56 million and capital expenditures -258,542, giving a free cash flow of 2.30 million.
| Operating Cash Flow | 2.56M |
| Capital Expenditures | -258,542 |
| Free Cash Flow | 2.30M |
| FCF Per Share | n/a |
Margins
Gross margin is 26.87%, with operating and profit margins of 11.74% and 8.13%.
| Gross Margin | 26.87% |
| Operating Margin | 11.74% |
| Pretax Margin | 11.09% |
| Profit Margin | 8.13% |
| EBITDA Margin | 12.49% |
| EBIT Margin | 11.74% |
| FCF Margin | 8.85% |
Dividends & Yields
BioRem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.59% |
| Shareholder Yield | -0.59% |
| Earnings Yield | 8.98% |
| FCF Yield | 9.78% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRem has an Altman Z-Score of 3.39.
| Altman Z-Score | 3.39 |
| Piotroski F-Score | n/a |